Characteristics | PFS | OS | ||
---|---|---|---|---|
Hazard ratios (95%CI) | P value | Hazard ratios (95%CI) | P value | |
Age (year) | ||||
  ≤ 45 | 1.0 |  |  |  |
  > 45 | 1.558 (1.054–2.302) | 0.026* |  |  |
Menopausal status | ||||
  Premenopausal | 1.0 |  |  |  |
  Postmenopausal | 0.745 (0.438–1.270) | 0.280 |  |  |
Number of metastatic sites | ||||
  < 2 | 1.0 |  | 1.0 |  |
  ≥ 2 | 1.679 (1.151–2.450) | 0.007* | 1.691 (1.087–2.630) | 0.020* |
Brain metastases | ||||
  No | 1.0 |  | 1.0 |  |
  Yes | 1.582 (1.019–2.453) | 0.041* | 1.833 (1.133–2.963) | 0.013* |
Duration of prior trastuzumab treatment | ||||
  < 6 months |  |  | 1.0 |  |
  ≥ 6 months |  |  | 0.863 (0.546–1.364) | 0.528 |